Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

380 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis.
Wilson C, Purcell C, Seaton A, Oladipo O, Maxwell PJ, O'Sullivan JM, Wilson RH, Johnston PG, Waugh DJ. Wilson C, et al. J Pharmacol Exp Ther. 2008 Dec;327(3):746-59. doi: 10.1124/jpet.108.143826. Epub 2008 Sep 9. J Pharmacol Exp Ther. 2008. PMID: 18780829
A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial).
van Dodewaard-de Jong JM, de Klerk JM, Bloemendal HJ, van Bezooijen BP, de Haas MJ, Wilson RH, O'Sullivan JM. van Dodewaard-de Jong JM, et al. Eur J Nucl Med Mol Imaging. 2011 Nov;38(11):1990-8. doi: 10.1007/s00259-011-1883-0. Epub 2011 Jul 27. Eur J Nucl Med Mol Imaging. 2011. PMID: 21792569 Clinical Trial.
Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program.
Lawler M, Gavin A, Salto-Tellez M, Kennedy RD, Van Schaeybroeck S, Wilson RH, Harkin DP, Grayson M, Boyd RE, Hamilton PW, McArt DG, James J, Robson T, Ladner RD, Prise KM, O'Sullivan JM, Harrison T, Murray L, Johnston PG, Waugh DJ. Lawler M, et al. Cancer. 2016 Mar 1;122(5):664-73. doi: 10.1002/cncr.29814. Epub 2015 Dec 22. Cancer. 2016. PMID: 26695702 Free PMC article.
Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma.
Armstrong CWD, Coulter JA, Ong CW, Maxwell PJ, Walker S, Butterworth KT, Lyubomska O, Berlingeri S, Gallagher R, O'Sullivan JM, Jain S, Mills IG, Prise KM, Bristow RG, LaBonte MJ, Waugh DJJ. Armstrong CWD, et al. NAR Cancer. 2020 Sep;2(3):zcaa012. doi: 10.1093/narcan/zcaa012. Epub 2020 Jul 3. NAR Cancer. 2020. PMID: 32743555 Free PMC article.
380 results